MX Orthopedics was awarded a $750,000 Accelerator Loan from the Massachusetts Life Sciences Center. Funds will support commercialization of Nitinol-based dynaMX™ superelastic orthopaedic fracture fixation implants.
The dynaMX line is intended to generate and sustain high levels of compression at the fracture site as bone remodels. MX Orthopedics received initial FDA 510(k) clearance for the device in late 2Q15, and clearance for a tabbed version in 1Q16. Both are indicated for use in the hand, foot and proximal tibia.
MX Orthopedics was awarded a $750,000 Accelerator Loan from the Massachusetts Life Sciences Center. Funds will support commercialization of Nitinol-based dynaMX™ superelastic orthopaedic fracture fixation implants.
The dynaMX line is intended to generate and sustain high levels of compression at the fracture site as bone remodels. MX...
MX Orthopedics was awarded a $750,000 Accelerator Loan from the Massachusetts Life Sciences Center. Funds will support commercialization of Nitinol-based dynaMX™ superelastic orthopaedic fracture fixation implants.
The dynaMX line is intended to generate and sustain high levels of compression at the fracture site as bone remodels. MX Orthopedics received initial FDA 510(k) clearance for the device in late 2Q15, and clearance for a tabbed version in 1Q16. Both are indicated for use in the hand, foot and proximal tibia.
Copy to clipboard 
